Phase 3 Study of Futuximab/Modotuximab in Combination With Trifluridine/Tipiracil Versus Trifluridine/Tipiracil Single Agent in Participants With Previously Treated Metastatic Colorectal Cancer
3상
조기 종료
NCT05223673
| 대상 질환 | Metastatic Colorectal Cancer |
|---|
| 임상 단계 | 3상 |
|---|
| 스폰서 | Institut de Recherches Internationales Servier |
|---|
| 상태 | 조기 종료 |
|---|
| 참여자 수 | 7 명 |
|---|
| 중재(약물) | Futuximab/modotuximab, Trifluridine/Tipiracil, Trifluridine/Tipiracil |
|---|
| 시작일 | 2022년 4월 21일 |
|---|
| 완료일 | 2023년 6월 21일 |
|---|
| 결과 공개일 | 2024년 3월 5일 |
|---|
요약
This is a randomized phase III study with a safety lead-in part in patients with KRAS/ NRAS and BRAF Wild Type metastatic colorectal cancer who have previously received treatment with oxaliplatin, irinotecan, fluoropyrimidines, anti-VEGF agents and anti-EGFR antibodies. The main objective of the safety lead-in part is to assess safety and tolerability of futuximab/modotuximab in combination with trifluridine/tipiracil. The primary objective of the phase III part is to compare Overall Survival of futuximab/modotuximab in combination with trifluridine/tipiracil vs trifluridine/tipiracil monotherapy in patients with tumours that are KRAS/NRAS and BRAF wild-type (WT).
Incidence of Dose-limiting Toxicities (DLTs) (Safety Lead-In Part)
End of cycle 1 (Each cycle is up to 28 days) · dose-limiting toxicities (DLTs)
| Futuximab/Modotuximab Combined With Trifluridine/Tipiracil (Safety Lead-In and Phase III Parts) | 0 dose-limiting toxicities (DLTs) |
|---|
Overall Survival (OS) (In Double Negative, KRAS/NRAS and BRAF Wild Type Patients) (Phase III Part)
up to 4 years 9 months
BENITIONS에서 보기
ClinicalTrials.gov 원문 보기
전체 임상
이 페이지는 ClinicalTrials.gov의 공개 데이터를 정리한 것입니다. 의학적 조언이 아니며 투자 권유나 자문도 아닙니다. 반드시 전문의와 상담하세요.